Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... November 25, 2014 The Pittcon marketing ... official conference and exposition mobile app, ... download in the App Store for iOS and Android ... resource tool before, during and after the event. It ... on exhibiting companies, technical sessions, Conferee Networking sessions and ...
    (Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
    (Date:11/26/2014)... 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il ... occasione di Hi Europe 2014 (dal 2 al 4 ... tratta della curcumina con la maggiore biodisponibilità di sempre, ... ingredienti approvati dalle norme europee. La curcumina ... curcumina ( Curcuma longa ) che è stata associata ...
    (Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
    Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
    ... SCOTTSDALE, Ariz. , Feb. 4 A ... cancer care in community oncology practices revealed that Medicare covers ... providing related infusion room services to seniors with cancer. The ... planning, care coordination, and follow-up care planning -- are not ...
    ... ... , ... (Vocus) February 4, 2010 -- Qteros, Inc. , a leading developer of second-generation ... announced today that Mick Sawka has joined the company as Vice President, Business Development, ...
    ... RESEARCH TRIANGLE PARK, N.C. , Feb. 4 ... orally available antiviral therapeutics, announced today that Gwendolyn Powell ... Medical Officer.   , Dr. Painter has more than 20 ... clinical development, clinical safety and pharmacovigilance, and occupational and environmental ...
    Cached Biology Technology:Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 2Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 4Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 2Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 3Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3
    (Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
    (Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
    (Date:11/15/2014)...  While we may still be a few years away ... Trek" to gain instant access to all that ailed his ... and tablets for monitoring and measuring our health are cropping ... seem a tad Orwellian to some, but a new survey ... technological opportunities into their healthcare regime. These are ...
    Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
    ... led to enormous advancements in the scientific field. Through ... gain valuable knowledge about causative and preventative factors for ... the wider availability of such information also has a ... Researchers from Tel Aviv University and the Whitehead ...
    ... government invested more than $25 billion in health information ... and Recovery Act; yet, little is known about how ... Now, a University of Missouri nursing informatics expert suggests ... communication strategies among clinical staff, which allows staff to ...
    ... Researchers from the Polytechnic University of Catalonia have developed ... a technique called electroporation, which involves opening pores in ... like drugs and DNA. Current methods are aggressive and ... voltage electroporation with a small printed circuit board, which ...
    Cached Biology News:A privacy risk in your DNA 2A privacy risk in your DNA 3Information Technology improves patient care and increases privacy, MU informatics expert says 2A Spanish breakthrough allows the electroporation of cell cultures for less than 1 Euro 2A Spanish breakthrough allows the electroporation of cell cultures for less than 1 Euro 3